BP C1
Alternative Names: BP-C1Latest Information Update: 09 Jul 2024
At a glance
- Originator Meabco
- Developer Meabco; Norwegian University of Life Sciences
- Class Antineoplastics; Platinum complexes
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer; Pancreatic cancer
- Preclinical Cancer
Most Recent Events
- 09 Jul 2024 Phase-III clinical trials in Breast cancer (Metastatic disease) (IM) prior to July 2024 (Meabco Pipeline, July 2024)
- 09 Jul 2024 Phase-III clinical trials in Pancreatic cancer (IM) prior to July 2024 (Meabco Pipeline, July 2024)
- 09 Jul 2024 Preclinical trials in Cancer in Denmark (unspecified route) prior to July 2024 (Meabco Pipeline, July 2024)